UTRN: A Potential Drug Target for Fetal Development and Survival

Target Name: UTRN

NCBI ID: G7402

UTRN

UTRN: A Potential Drug Target for Fetal Development and Survival

UTRN, or Utrophin, transcript variant 1, is a protein that is expressed in the human placenta and has been shown to play a role in several important processes that are critical for fetal development and survival. UTRN is a member of the utrophin family, which includes a group of transmembrane proteins that are characterized by the presence of a unique C-terminal region that is involved in their unique functions.

The utrophin family has been identified as a potential drug target due to its involvement in a variety of physiological processes, including the regulation of cell adhesion, the establishment of normal tissue structure and the maintenance of neural tube development. In addition, utrophin has also been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and developmental disorders.

One of the key functions of UTRN is its role in the regulation of cell adhesion. During fetal development, UTRN helps to maintain the integrity of the neural tube, which will eventually become the brain and spinal cord. UTRN is thought to do this by interacting with a variety of cell types and molecules, including the cytoskeleton, the extracellular matrix (ECM), and specific proteins that are involved in cell adhesion.

In addition to its role in cell adhesion, UTRN is also involved in the regulation of neural tube development. During embryonic development, UTRN helps to ensure that the neural tube forms properly and that it becomes a normal part of the brain and spinal cord. This is thought to be done through the regulation of the cellulose material that makes up the neural tube, as well as the formation of specific neural tube structures.

UTRN has also been shown to play a role in the regulation of cell proliferation and apoptosis, which are important processes that are critical for the growth and development of tissues. In addition, UTRN has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed.

In addition to its role in cell regulation, UTRN has also been shown to play a role in the development and progression of several diseases, including cancer. For example, studies have shown that UTRN is often expressed in various types of cancer and that it is involved in the regulation of cell growth and apoptosis. In addition, UTRN has also been shown to play a role in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Due to its involvement in so many important processes, UTRN has been identified as a potential drug target. Studies have shown that UTRN can be targeted with small molecules, antibodies and other therapeutic agents that are designed to interact with its unique C-terminal region. In addition, researchers have also shown that targeting UTRN with small molecules has the potential to be a highly effective way to treat a variety of diseases, including cancer, neurodegenerative diseases and developmental disorders.

In conclusion, UTRN, or Utrophin, transcript variant 1 is a protein that is expressed in the human placenta and plays a critical role in several important processes that are critical for fetal development and survival. UTRN is a member of the utrophin family and has been shown to play a role in the regulation of cell adhesion, neural tube development, cell proliferation and apoptosis, and angiogenesis. Additionally, UTRN has been shown to play a role in the development and progression of several diseases, including cancer and neurodegenerative diseases. Given its involvement in so many important processes, UTRN has the potential to be a drug target for a variety of diseases.

Protein Name: Utrophin

Functions: May play a role in anchoring the cytoskeleton to the plasma membrane

The "UTRN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UTRN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets